MarketInOut Stock Screener Log In | Sign Up
 

Lantern Pharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/15/2026 16:00
Lantern Pharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization34.14 mln
Float8.57 mln
Earnings Date05/15/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

98 / 100
Top performer

Debt / Equity

0.01
Debt-free

ROE

-129
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Lantern Pharma is a Dallas-based drug development company focused entirely on cancer treatment, using artificial intelligence to guide its research and improve the chances of success for its drug candidates. The company is advancing several drugs through clinical trials targeting difficult-to-treat cancers, including lung cancer, pancreatic cancer, brain tumors, and certain blood cancers. Lantern also works with a number of outside partners to expand its pipeline, combining its AI-driven approach with external expertise to develop treatments for both common and rare cancer types. Founded in 2013, the company continues to build on its technology platform to make cancer drug development faster and more precise.

Key Fundamentals

EPS-1.57
ROE-129
ROIC-4,805
ROA-96.44
EBITDA, mln-17.96
EV / EBITDA-0.97
EV / EBIT-0.97

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio1.73
Short % of Float17.90

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 49.52% 99 / 100   
1 Month 23.62% 93 / 100   
2 Months 18.94% 85 / 100   
6 Months -9.77% 31 / 100   
1 Year -22.66% 22 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us